{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Obstructive+Pulmonary+Disease+COPD&page=2",
    "query": {
      "condition": "Chronic Obstructive Pulmonary Disease COPD",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Obstructive+Pulmonary+Disease+COPD&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T14:28:10.397Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00889447",
      "title": "Screening Evaluation for Studies of Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "40 Years to 100 Years"
      },
      "enrollment_count": 670,
      "start_date": "2008-01",
      "completion_date": "2017-05",
      "has_results": false,
      "last_update_posted_date": "2018-03-12",
      "last_synced_at": "2026-06-26T14:28:10.397Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00889447"
    },
    {
      "nct_id": "NCT04155684",
      "title": "Dysbiosis Impact on Lung Disease in HIV",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections",
        "COPD",
        "Microbiome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 50,
      "start_date": "2018-11-01",
      "completion_date": "2022-10-01",
      "has_results": false,
      "last_update_posted_date": "2025-04-03",
      "last_synced_at": "2026-06-26T14:28:10.397Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04155684"
    },
    {
      "nct_id": "NCT04155047",
      "title": "A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Glyocopyrrolate Inhalation Solution administered by Magnair",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo administered by Magnair",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Sunovion Respiratory Development Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "40 Years to 99 Years"
      },
      "enrollment_count": 44,
      "start_date": "2019-11-07",
      "completion_date": "2020-03-31",
      "has_results": true,
      "last_update_posted_date": "2021-05-10",
      "last_synced_at": "2026-06-26T14:28:10.397Z",
      "location_count": 1,
      "location_summary": "Saint Charles, Missouri",
      "locations": [
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04155047"
    },
    {
      "nct_id": "NCT00346749",
      "title": "ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Salmeterol",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate/Salmeterol Combination Product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2006-12",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2016-10-28",
      "last_synced_at": "2026-06-26T14:28:10.397Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00346749"
    },
    {
      "nct_id": "NCT00903955",
      "title": "Mucus Dehydration and Evolution of Chronic Obstructive Pulmonary Disease (COPD) Lung Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease",
        "Chronic Bronchitis"
      ],
      "interventions": [
        {
          "name": "7% hypertonic saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "82 Years",
        "sex": "ALL",
        "summary": "18 Years to 82 Years"
      },
      "enrollment_count": 100,
      "start_date": "2006-09",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2013-02-07",
      "last_synced_at": "2026-06-26T14:28:10.397Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00903955"
    },
    {
      "nct_id": "NCT01551316",
      "title": "Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "MN-221",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediciNova",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 19,
      "start_date": "2012-03",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2012-05-21",
      "last_synced_at": "2026-06-26T14:28:10.397Z",
      "location_count": 2,
      "location_summary": "New Braunfels, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "New Braunfels",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01551316"
    },
    {
      "nct_id": "NCT03636347",
      "title": "A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency",
        "Emphysema",
        "COPD"
      ],
      "interventions": [
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Alvelestat oral tablet - dose 1",
          "type": "DRUG"
        },
        {
          "name": "Alvelestat oral tablet - dose 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mereo BioPharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 99,
      "start_date": "2018-10-29",
      "completion_date": "2022-03-30",
      "has_results": false,
      "last_update_posted_date": "2022-04-14",
      "last_synced_at": "2026-06-26T14:28:10.397Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03636347"
    },
    {
      "nct_id": "NCT02099799",
      "title": "The Effect of Physical Activity Promotion on Short and Long-term Outcomes in COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COPD",
        "Emphysema",
        "Chronic Bronchitis"
      ],
      "interventions": [
        {
          "name": "Pedometer and Website",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2015-11-17",
      "completion_date": "2020-02-07",
      "has_results": true,
      "last_update_posted_date": "2021-09-05",
      "last_synced_at": "2026-06-26T14:28:10.397Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Boston, Massachusetts",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02099799"
    },
    {
      "nct_id": "NCT00606684",
      "title": "A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "GW642444 6.25",
          "type": "DRUG"
        },
        {
          "name": "GW642444 3mcg",
          "type": "DRUG"
        },
        {
          "name": "GW642444 12.5mcg",
          "type": "DRUG"
        },
        {
          "name": "GW642444 25mcg",
          "type": "DRUG"
        },
        {
          "name": "GW642444 50mcg",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 602,
      "start_date": "2008-02",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2016-12-16",
      "last_synced_at": "2026-06-26T14:28:10.397Z",
      "location_count": 49,
      "location_summary": "Florence, Alabama • Jasper, Alabama • Montgomery, Alabama + 45 more",
      "locations": [
        {
          "city": "Florence",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00606684"
    },
    {
      "nct_id": "NCT03546907",
      "title": "Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "SAR440340",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Any Inhaled Corticosteroids as prescribed by treating physician as standard of care",
          "type": "DRUG"
        },
        {
          "name": "Any Long Acting Beta Agonist as prescribed by treating physician as standard of care",
          "type": "DRUG"
        },
        {
          "name": "Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care",
          "type": "DRUG"
        },
        {
          "name": "Any short-acting β agonist as prescribed by treating physician as standard of care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 343,
      "start_date": "2018-07-16",
      "completion_date": "2020-02-21",
      "has_results": true,
      "last_update_posted_date": "2022-11-22",
      "last_synced_at": "2026-06-26T14:28:10.397Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Riverside, California • Rolling Hills Estates, California + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Westminster",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03546907"
    }
  ]
}